Trial Profile
Expanded Access for AG-221
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 30 Oct 2019
Price :
$35
*
At a glance
- Drugs Enasidenib (Primary)
- Indications Acute myeloid leukaemia
- Focus Expanded access; Therapeutic Use
- Sponsors Celgene Corporation
- 18 Dec 2018 Status changed from recruiting to completed.
- 02 Nov 2018 New trial record